Vitamin B12 and Folic Acid: study protocols
71 study groups took Vitamin B12 together with Folic Acid. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Vitamin B12
71 study groups in 64 studies say how much Vitamin B12 participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mcg to 500 mcg, 37% of 71 study groups.
| Daily dose | Study groups |
|---|---|
| 1 mcg or less | 1 |
| 1 mcg to 2.5 mcg | 6 |
| 2.5 mcg to 5 mcg | 9 |
| 5 mcg to 10 mcg | 9 |
| 10 mcg to 25 mcg | 0 |
| 25 mcg to 50 mcg | 3 |
| 50 mcg to 100 mcg | 0 |
| 100 mcg to 250 mcg | 0 |
| 250 mcg to 500 mcg | 26 |
| 500 mcg to 1 mg | 12 |
| 1 mg to 2.5 mg | 3 |
| over 2.5 mg | 2 |
Dose per serving from research: Folic Acid
69 study groups in 62 studies say how much Folic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mcg to 1 mg, 33% of 69 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mcg or less | 1 |
| 100 mcg to 250 mcg | 9 |
| 250 mcg to 500 mcg | 17 |
| 500 mcg to 1 mg | 23 |
| 1 mg to 2.5 mg | 10 |
| 2.5 mg to 5 mg | 8 |
| over 5 mg | 1 |
Commonly used together
56 of 71 study groups took Vitamin B12 and Folic Acid with something else. Shown: what 3 or more different studies gave. The 10 most common of 14.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B6 | 46 |
| Iron | 12 |
| Riboflavin | 10 |
| Vitamin A | 10 |
| Vitamin C | 10 |
| Vitamin E | 10 |
| Zinc | 9 |
| Selenium | 7 |
| Vitamin D | 7 |
| Copper | 6 |
71 study groups
| Study | ||||
|---|---|---|---|---|
| Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors 2007 · Homocysteine-lowering group · Myocardial infarction survivors | 1 mg | 2 mg | 6 years | — |
| Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial 2012 · B-vitamins group · Adults with a stroke or transient ischaemic attack within the previous 7 months; men and women, age not restricted | 500 mcg | 2 mg | 1241 days | 4,040 |
| Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study 2009 · folic acid/B6/B12 group · Women at high risk of cardiovascular disease, with preexisting cardiovascular disease or at least three coronary risk factors; women included in these AMD analyses had no AMD diagnosis at baseline. | 1 mg | 2.5 mg | 2665 days | 2,607 |
| Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial 2008 · combined folic acid/vitamin B6/vitamin B12 treatment · Women aged 40 years or older with a history of cardiovascular disease or at least three coronary risk factors | 1 mg | 2.5 mg | 2666 days | — |
| Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial 2009 · vitamin therapy group · Adults with known cardiovascular disease | 1 mg | 2.5 mg | 5 years | — |
| B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial 2010 · B-vitamins · Stroke survivors; age and sex not specified | 500 mcg | 2 mg | 383 days | — |
| Folic Acid and Vitamin B12 Supplementation and the Risk of Cancer: Long-term Follow-up of the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) Trial 2019 · B vitamins · B-PROOF trial participants; age and specific condition not stated in the abstract | 500 mcg | 400 mcg | 3 years | — |
| Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial 2002 · homocysteine-lowering therapy · Patients with coronary artery disease after successful percutaneous coronary intervention; age and sex not specified | 400 mcg | 1 mg | 26 weeks | 272 |
| Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial 2005 · daily oral treatment with folate and mecobalamin · Adults aged 65 years or older with residual hemiplegia at least 1 year after a first ischemic stroke | 1.5 mg | 5 mg | 2 years | — |
| Effectiveness of homocysteine lowering vitamins in prevention of thrombotic tendency at high altitude area: A randomized field trial 2015 · intervention · Indian soldiers freshly inducted to a high-altitude area | 1 mg | 5 mg | 2 years | — |